Don't Just Read the News, Understand It.
Published loading...Updated

Experimental Obesity Drug Shows Promise

  • The UK's medicines regulator issued guidance on weight loss drugs for women of reproductive age due to reports of unintended pregnancies by users.
  • This guidance followed 40 reports of pregnancies and a 2024 study showing tirzepatide reduced ethinylestradiol levels by 20%, possibly lowering oral contraceptive effectiveness.
  • Women taking oral contraceptives are recommended to use an additional non-oral contraceptive method, such as condoms, during the first month of initiating semaglutide or tirzepatide treatment, since fertility may increase regardless of contraceptive use.
  • Side effects like vomiting and diarrhea affect 12% and 23% of tirzepatide users, respectively, which can reduce contraceptive effectiveness and lead to unintended pregnancies.
  • The guidance highlights safety uncertainties around these drugs in pregnancy and suggests women consult doctors if they become pregnant while using weight loss medications.
Insights by Ground AI
Does this summary seem wrong?

22 Articles

All
Left
4
Center
8
Right
2
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 57% of the sources are Center
57% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

WTVB broke the news in on Friday, June 13, 2025.
Sources are mostly out of (0)